Your browser doesn't support javascript.
loading
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.
Sullivan, Kathleen M C; Vilalta, Marta; Ertl, Linda S; Wang, Yu; Dunlap, Carolyn; Ebsworth, Karen; Zhao, Bin N; Li, Shijie; Zeng, Yibin; Miao, Zhenhua; Fan, Pingchen; Mali, Venkat; Lange, Christopher; McMurtrie, Darren; Yang, Ju; Lui, Rebecca; Scamp, Ryan; Chhina, Vicky; Kumamoto, Alice; Yau, Simon; Dang, Ton; Easterday, Ashton; Liu, Shirley; Miao, Shichang; Charo, Israel; Schall, Thomas J; Zhang, Penglie.
Afiliação
  • Sullivan KMC; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Vilalta M; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Ertl LS; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Wang Y; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Dunlap C; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Ebsworth K; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Zhao BN; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Li S; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Zeng Y; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Miao Z; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Fan P; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Mali V; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Lange C; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • McMurtrie D; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Yang J; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Lui R; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Scamp R; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Chhina V; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Kumamoto A; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Yau S; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Dang T; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Easterday A; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Liu S; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Miao S; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Charo I; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Schall TJ; ChemoCentryx, Inc., San Carlos, California, United States of America.
  • Zhang P; ChemoCentryx, Inc., San Carlos, California, United States of America.
PLoS One ; 18(6): e0286724, 2023.
Article em En | MEDLINE | ID: mdl-37285333
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígeno B7-H1 / Neoplasias Tipo de estudo: Clinical_trials Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígeno B7-H1 / Neoplasias Tipo de estudo: Clinical_trials Limite: Animals / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article